News Column

Kalon and the Texas Biocorridor will be front and center at BIO International Convention

June 19, 2014

College Station, Texas (PRWEB) June 19, 2014

Kalon Biotherapeutics has led the first wave of drug development and biologics manufacturing in the Texas Biocorridor, the epicenter of Texas' emerging biotech industry. The Texas Biocorridor has a prominent presence at the premier global biotechnology event, the BIO International Convention, which takes place in San DiegoJune 23-26.

Kalon recently broke ground on its second manufacturing facility, a state-of-the-art vaccine facility, where it will manufacture components of an influenza vaccine for GlaxoSmithKline and boost the nation's ability to produce a variety of vaccines and other countermeasures in response to a pandemic. The facility will further anchor the Center for Innovation in Advanced Development and Manufacturing (CIADM), created through a $285.6 million public-private partnership with the U.S. Department of Health and Human Services.

"The Texas Biocorridor is exploding with new activity," said Andrew Strong, president and chief executive officer of Kalon. "It truly is becoming the third coast for biotech, as companies from across the nation are seeing the value of locating in the corridor's business-friendly environment, with access to a large, highly qualified workforce. With their presence at BIO, the Texas Biocorridor companies provide easy access to potential businesses interested in Texas."

Located in College Station near Texas A&M University with close proximity to the Texas Medical Center in Houston, the Texas Biocorridor is a premier biotech location in the manufacturing of biologics and pharmaceuticals. Biotech companies from across the globe are accessing the Texas Biocorridor's biotech services and infrastructure to speed their drug and medical device products to market. Kalon sets the example through its innovative approach to biologics manufacturing and working with leading biopharmaceutical companies to get their drugs to market efficiently and affordably.

The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech. The event offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry.

Officials from at least a half dozen Texas Biocorridor companies and organizations will attend BIO this year, including Kalon Biotherapeutics, the National Center for Therapeutics Manufacturing (NCTM), the Center for Innovation in Advanced Development and Manufacturing (CIADM), Texas A&M Health Science Center (TAMHSC), the Texas A&M Institute for Preclinical Studies (TIPS), ATLAS, and the Research Valley Partnership.

The BIO International Convention features keynotes and sessions from key policymakers, scientists, CEOs, and celebrities. This year, former Secretary of State Hillary Clinton and Sir Richard Branson, the founder of the Virgin Group, one of the world's most recognized and respected brands, will deliver the keynote addresses.

"Two years ago, the Texas Biocorridor was just a vision," said Todd McDaniel, CEcD, president and chief executive officer of The Research Valley Partnership. "Now, these companies and others are breaking ground on new facilities or are already here. We have a whole master-planned community centered on biotechnology and pharmaceutical manufacturing. The Texas Biocorridor truly has the most leading-edge structure in biotechnology in the nation, and we intend to tell that story vividly and effectively at this year's BIO International Convention."


Additional Information:

The National Center for Therapeutics Manufacturing (NCTM).A first-of-its-kind multidisciplinary workforce education institution and biopharmaceutical manufacturing center located at Texas A&M University, NCTM delivers customizable professional development short courses, workshops and job-specific training led-by industry-experienced instructor.

The Center for Innovation in Advanced Development and Manufacturing (CIADM).Founded on an initial $285.6 million public-private partnership with the U.S. Department of Health and Human Services, the Texas A&M CIADM is designed to enhance the nation's emergency preparedness against emerging infectious diseases, including pandemic influenza and chemical, biological, radiological and nuclear threats.

Texas A&M Health Science Center (TAMHSC).

A unit of Texas A&M University, TAMHSC is transforming health through innovative research and education in dentistry, medicine, nursing, pharmacy, public health and medical sciences, and provides a highly educated and trained workforce for Texas Biocorridor companies.

Texas A&M Institute for Preclinical Studies (TIPS). An institute within Texas A&M University and directly associated with the TAMU College of Veterinary Medicine and Biomedical Sciences, TIPS provides large animal GLP and translational research studies with unique access to expertise in all major medical and scientific disciplines. With unique resources and collaboration with the Texas A&M College of Veterinary Medicine and Biomedical Sciences, TIPS facilitates the inclusion of animals with naturally occurring disease as viable research models. TIPS provides unique opportunities to develop new therapeutics in the fields of oncology, cardiology, immunology, endocrinology, and an array of genetic disorders common to humans and companion animals.

ATLAS. ATLAS is the first and only master planned community in Texas designed for companies engaged in the manufacturing of biologics and pharmaceuticals. Located in the heart of the Texas A&M Biocorridor, ATLAS offers unparalleled access and proximity to world-class researchers and students, providing the ideal, collaborative atmosphere companies need to attract and retain world-class talent.

Research Valley Partnership (RVP). The RVP works with medical device, pharmaceutical and biotechnology companies by connecting them to the unique resources and solutions network in the Texas Biocorridor.

About Kalon Biotherapeutics

Kalon Biotherapeutics is a private company formed by The Texas A&M University System in spring 2011. It was formed to provide advanced biologics development manufacturing in the National Center for Therapeutics Manufacturing (NCTM), a state-of-the-art cGMP flexible biomanufacturing facility that utilizes self-contained, mobile clean rooms (MCRs) for conducting multiple biomanufacturing projects in a ballroom environment, all under a single roof. Kalon enables rapid, cost-effective drug development through a flexible and scalable clinical manufacturing platform with capabilities to support all classes of biological drug products, including vaccines, monoclonal antibodies, cellular and gene therapies. Kalon is a key partner of the Texas Biocorridor's "One-Stop-Shop" Biotech Infrastructure Pipeline, to discover new therapies in plant, animal and human health; perform preclinical evaluations; and utilize flexible, scalable Biotech Infrastructure Pipeline biopharmaceutical manufacturing, all in one convenient location.

About the BIO International Convention

The BIO International Convention is hosted by the Biotechnology Industry Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other countries. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. The BIO International Convention helps BIO fulfill its mission to help grow the global biotech industry. Profits from the BIO International Convention are returned to the biotechnology industry by supporting BIO programs and initiatives. BIO works throughout the year to create a policy environment that enables the industry to continue to fulfill its vision of bettering the world through biotechnology innovation.

Read the full story at

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: PR Web

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters